Binding interactions between human serum albumin (HSA) and four approved epidermal
growth factor receptor (EGFR) inhibitors gefitinib (GEF), erlotinib (ERL), afatinib (AFA) …

Binding of gefitinib (GEF), a promising anticancer drug to human serum albumin (HSA), the
major transport protein in blood circulation was investigated using fluorescence, UV-vis …

Human serum albumin (HSA) is a globular and monomeric protein in plasma that transports
many drugs and compounds. Binding of some drugs to HSA can lead to changes in its …

Binding towards human serum albumin (HSA) and α1-acid glycoprotein (AGP) of three
approved fibroblast growth factor receptor (FGFR) inhibitors ponatinib (PON), nintedanib …

The interaction between erlotinib and human serum albumin (HSA) in simulated
physiological conditions was investigated by spectroscopic methods. The results revealed …

Methods The BSA solution (0.1 mM) was prepared daily in Tris buffer (0.05 mol l-1, pH= 7.4)
and treated at final concentration of 1.67× 10-5 M with different amounts of erlotinib …

The utilization of BRAF and MEK inhibitors in combination therapy has demonstrated
superior outcomes in the treatment of melanoma as compared to monotherapy. In the …

Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to
differences in treatment outcome. Unbound drug concentrations are believed to be more …

The interaction of afatinib (AFB) with bovine serum albumin (BSA) was examined via
fluorescence and UV-Vis spectroscopy. Spectrofluorimetric measurements revealed that …

Experimental studies have demonstrated that L858R mutation in the EGF receptor (EGFR)
confers tumor sensitivity whereas T790M and L858R/T790M mutations cause resistance to …